Innocoll's CollaGUARD dressing:
This article was originally published in Clinica
Executive Summary
Innocoll has received its first regulatory approval in the US, after its wholly-owned subsidiary, Innocoll Pharmaceuticals, gained 510k clearance for its advanced wound care product, CollaGUARD. The collagen-based dressing, which incorporates the firm's CollaRx membrane technology, can be used to manage superficial and deep wounds. The worldwide market for advanced wound care dressings is worth well over $1bn, the Ashburn, Virginia firm said, adding that because CollaGUARD can be manufactured using a "highly efficient and cost-effective process", it can compete "very favourably" against other collagen-based wound care products. CollaGUARD is already approved in Europe. Follow-up products currently in development include a silver-impregnated version of CollaGUARD for infected wounds or wounds at risk of infection, and DermaSIL, a collagen-synthetic foam composite dressing for deep and heavily exuding wounds.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.